SLXN

Silexion Therapeutics Ltd. NASDAQ Listed Aug 16, 2024

Healthcare ·Biotechnology ·IL · silexion.com

$0.52

Mkt Cap $291,140

52w Low $0.47 0.2% of range 52w High $22.36

50d MA $1.24 200d MA $3.42

P/E (TTM) -0.1x

EV/EBITDA 0.3x

P/B 0.3x

Debt/Equity 0.2x

ROE -457.6%

P/FCF -0.2x

RSI (14) —

ATR (14) —

Beta 0.06

50d MA $1.24

200d MA $3.42

Avg Volume 49.5K

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

SIC Code

2836

CIK (SEC)

2022416

Phone

972 2 674 3430

The Goldyne Savad Institute of Gene Therapy · Jerusalem, L3 9112001 · IL

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 17, 2026	AMC	-1.17	-2.38	-103.8%	1.56	+3.2%	-1.9%	-5.9%	-15.3%	+4.1%	+5.5%	—
Nov 12, 2025	AMC	-3.40	-2.88	+15.3%	2.91	+0.0%	-1.4%	-1.0%	-9.2%	-0.4%	-3.9%	—
Aug 12, 2025	AMC	-3.15	-4.32	-37.1%	7.25	+2.3%	+2.1%	-0.5%	-1.6%	+3.3%	-4.8%	—
May 13, 2025	AMC	-0.22	-3.90	-1672.7%	14.55	+0.0%	-1.0%	+0.4%	-5.0%	+1.9%	-3.1%	—
Mar 18, 2025	AMC	-0.98	-20.76	-2018.4%	18.75	-1.6%	-11.2%	+0.0%	+2.7%	-1.8%	+6.2%	—
Nov 14, 2024	AMC	-7.38	-18.27	-147.6%	30.15	+0.0%	-5.0%	+5.2%	+1.5%	+47.1%	-4.0%	—
Aug 13, 2024	AMC	—	-0.99	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	Maxim Group	Maintains	Buy → Buy	—	$16.65	$16.80	+0.9%	+0.0%	+2.7%	-1.8%	+6.2%	-2.5%

Data updated apr 27, 2026 1:49am · Source: massive.com